BACKGROUND: Idiopathic pneumonia syndrome (IPS) is a severe complication that can occur after hematopoietic stem cell transplantation (HSCT) and is often associated with a fatal outcome despite intensive supportive care. PROCEDURE: To assess the incidence and risk factors of IPS, we reviewed 251 consecutive patients (median age, 7.0 years) who received HSCT at the Department of Pediatrics, Nagoya University Hospital, between January 1990 and July 2009. RESULTS: Twenty of 251 (cumulative incidence of IPS at 2 years after HSCT, 8.0%; 95% confidence interval (CI), 5.1-12.4%) patients developed IPS. The median duration from HSCT to diagnosis of IPS was 67 days (range, 12-486 days). Patients with IPS had significantly higher 5-year transplant-related mortality compared to patients without IPS (52% (95% CI, 19-77%) vs. 13% (95% CI, 5-25%), P < 0.001), and the probability of 5-year overall survival was significantly worse for patients with IPS (42% (95% CI, 25-64%) vs. 68% (95% CI, 59-76%), P = 0.01). By multivariate analysis, high risk in underlying disease (HR, 2.5; 95% CI, 1.0-6.7; P = 0.05) and a busulfan-containing regimen (HR, 3.5; 95% CI, 1.3-9.9; P < 0.01) were identified as the independent risk factors for developing IPS. CONCLUSION: The prophylactic strategies for IPS in patients with these risk factors were warranted.
BACKGROUND:Idiopathic pneumonia syndrome (IPS) is a severe complication that can occur after hematopoietic stem cell transplantation (HSCT) and is often associated with a fatal outcome despite intensive supportive care. PROCEDURE: To assess the incidence and risk factors of IPS, we reviewed 251 consecutive patients (median age, 7.0 years) who received HSCT at the Department of Pediatrics, Nagoya University Hospital, between January 1990 and July 2009. RESULTS: Twenty of 251 (cumulative incidence of IPS at 2 years after HSCT, 8.0%; 95% confidence interval (CI), 5.1-12.4%) patients developed IPS. The median duration from HSCT to diagnosis of IPS was 67 days (range, 12-486 days). Patients with IPS had significantly higher 5-year transplant-related mortality compared to patients without IPS (52% (95% CI, 19-77%) vs. 13% (95% CI, 5-25%), P < 0.001), and the probability of 5-year overall survival was significantly worse for patients with IPS (42% (95% CI, 25-64%) vs. 68% (95% CI, 59-76%), P = 0.01). By multivariate analysis, high risk in underlying disease (HR, 2.5; 95% CI, 1.0-6.7; P = 0.05) and a busulfan-containing regimen (HR, 3.5; 95% CI, 1.3-9.9; P < 0.01) were identified as the independent risk factors for developing IPS. CONCLUSION: The prophylactic strategies for IPS in patients with these risk factors were warranted.
Authors: Gregory A Yanik; Mary M Horowitz; Daniel J Weisdorf; Brent R Logan; Vincent T Ho; Robert J Soiffer; Shelly L Carter; Juan Wu; John R Wingard; Nancy L Difronzo; James L Ferrara; Sergio Giralt; David K Madtes; Rebecca Drexler; Eric S White; Kenneth R Cooke Journal: Biol Blood Marrow Transplant Date: 2014-03-07 Impact factor: 5.742
Authors: Sachiko Seo; Jeffrey Yu; Isaac C Jenkins; Wendy M Leisenring; Terry Steven-Ayers; Jane M Kuypers; Meei-Li Huang; Keith R Jerome; Michael Boeckh; Sophie Paczesny Journal: Biol Blood Marrow Transplant Date: 2017-12-06 Impact factor: 5.742
Authors: H Sano; R Kobayashi; A Iguchi; D Suzuki; K Kishimoto; K Yasuda; K Kobayashi Journal: Bone Marrow Transplant Date: 2013-08-19 Impact factor: 5.483
Authors: Gregory A Yanik; Stephan A Grupp; Michael A Pulsipher; John E Levine; Kirk R Schultz; Donna A Wall; Bryan Langholz; Christopher C Dvorak; Keith Alangaden; Rakesh K Goyal; Eric S White; Jennifer M Collura; Micah A Skeens; Saada Eid; Elizabeth M Pierce; Kenneth R Cooke Journal: Biol Blood Marrow Transplant Date: 2014-09-28 Impact factor: 5.742
Authors: Sagar S Patel; Kwang Woo Ahn; Manoj Khanal; Caitrin Bupp; Mariam Allbee-Johnson; Navneet S Majhail; Betty K Hamilton; Seth J Rotz; Hasan Hashem; Amer Beitinjaneh; Hillard M Lazarus; Maxwell M Krem; Tim Prestidge; Neel S Bhatt; Akshay Sharma; Shahinaz M Gadalla; Hemant S Murthy; Larisa Broglie; Taiga Nishihori; César O Freytes; Gerhard C Hildebrandt; Usama Gergis; Sachiko Seo; Baldeep Wirk; Marcelo C Pasquini; Bipin N Savani; Mohamed L Sorror; Edward A Stadtmauer; Saurabh Chhabra Journal: Transplant Cell Ther Date: 2022-03-18
Authors: Sachiko Seo; Christian Renaud; Jane M Kuypers; Charles Y Chiu; Meei-Li Huang; Erik Samayoa; Hu Xie; Guixia Yu; Cynthia E Fisher; Ted A Gooley; Steven Miller; Robert C Hackman; David Myerson; Ruth H Sedlak; Yae-Jean Kim; Takahiro Fukuda; David N Fredricks; David K Madtes; Keith R Jerome; Michael Boeckh Journal: Blood Date: 2015-04-27 Impact factor: 22.113
Authors: Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan Journal: Ann Am Thorac Soc Date: 2021-03
Authors: David S Wenger; Matthew Triplette; Kristina Crothers; Guang-Shing Cheng; Joshua A Hill; Filippo Milano; Shahida Shahrir; Gary Schoch; Lisa K Vande Vusse Journal: Biol Blood Marrow Transplant Date: 2019-10-09 Impact factor: 5.742